1
|
Navaratnarajah A, El-Sherbini N, Brown EA. Long-term outcomes in patients with encapsulating peritoneal sclerosis managed with nutritional support. ARCH ESP UROL 2020; 40:487-495. [PMID: 32067553 DOI: 10.1177/0896860819893565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Little is known about long-term survivors with encapsulating peritoneal sclerosis (EPS). Published literature focuses on patients managed surgically. We describe our experience of the long-term outcomes in patients with EPS conservatively managed with nutritional support alone. METHODS This is a single-centre retrospective observational study of patients who had survived for ≥5 years since diagnosis. EPS survivors were invited for review of symptoms, nutritional assessment and evaluation of quality of life. Radiological progression was assessed based on serial computed tomography (CT) scores for each patient. RESULTS A total of 23 patients with a diagnosis of EPS for at least 5 years were identified, with 18 patients alive at the time of the study. Of these 18 patients, 10 patients transferred to haemodialysis (HD) and 8 patients received kidney transplants. Commonest symptoms were nausea (91%) and vomiting (73%). Mean body mass index for patients was within the ideal and healthy range, with only 11% suffering from continued weight loss. In all, 70% EPS survivors on HD received nutritional support compared to 15% of those with transplants; 17% required ongoing parenteral nutrition. Of the 11 patients with serial CT scans at least 4 years apart, 10 had an increase in radiological score for EPS but with no apparent correlation to clinical outcomes. There were no significant differences in the reported quality of life between EPS survivors on HD and those transplanted, with self-rated health status equivalent to that reported for the general end-stage kidney disease (ESKD) population. CONCLUSION Long-term survival following EPS managed conservatively with nutritional support is feasible, with the majority no longer requiring nutritional support and having a quality of life similar to other patients with ESKD.
Collapse
Affiliation(s)
- Arunraj Navaratnarajah
- Imperial College Renal and Transplant Centre, 8946Imperial College Healthcare NHS Trust, London, UK
| | - Nevine El-Sherbini
- Imperial College Renal and Transplant Centre, 8946Imperial College Healthcare NHS Trust, London, UK
| | - Edwina A Brown
- Imperial College Renal and Transplant Centre, 8946Imperial College Healthcare NHS Trust, London, UK
| |
Collapse
|
2
|
Tseng CC, Chen JB, Wang IK, Liao SC, Cheng BC, Wu AB, Chang YT, Hung SY, Huang CC. Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS. PLoS One 2018; 13:e0190079. [PMID: 29293548 PMCID: PMC5749741 DOI: 10.1371/journal.pone.0190079] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2017] [Accepted: 12/07/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of long-term peritoneal dialysis (PD). However, previous studies reported large variations in its mortality rates that may associate with a different degree of EPS severity. This study reports the incidence and outcomes of EPS and identifies the risk factors associated with severe EPS. METHODS We retrospectively analyzed clinical data of EPS patients from 3 medical centers in Taiwan from January 1982 to September 2015, and classified patients as having mild/moderate or severe EPS. Patients with intractable intestinal obstruction/gut-related sepsis that needed surgical intervention or resulted in mortality were in severe EPS group. Follow-up for outcome was through December 31, 2015. Clinical characteristics, peritoneal dialysis (PD)-related parameters, biochemical and imaging results were analyzed and compared between groups. RESULTS Fifty-eight of 3202 patients undergoing PD during the study period had EPS (prevalence 1.8%). The incidence of EPS increased for patients on PD for >6-8 years (≤6 yrs. vs. >6-8 yrs., 0.0% vs. 1.8%, p = 0.001). Relative to those on PD for >6-8 years, the risk of EPS significantly increased with PD duration longer than 10 years (>10-12 years vs. >6-8 years: OR: 5.5, 95% CI: 1.7-17.1, p < 0.01). Twenty-three patients fulfilled the criteria for severe EPS. The overall mortality rate of EPS was 35% (20/58), and was 74% (17/23) in the severe EPS group. The average serum levels of C-reactive protein (CRP) and intact-parathyroid hormone (i-PTH), which were checked every 3~6 months within one year before diagnosis of EPS, were higher in severe EPS group than in mild/moderate group (p = 0.02, p = 0.08, respectively). Multivariate analysis revealed severe EPS was independently associated with bowel tethering (based on CT), presentation with bloody ascites, diagnosis of EPS after withdrawal from PD, and i-PTH ≥ 384 pg/mL. Receiver operating characteristic analysis indicated that presentation with 2 or more of the 5 risk factors (EPS diagnosis after PD withdrawal, bloody ascites, bowel tethering, CRP ≥ 29 mg/L, and i-PTH ≥ 384 pg/mL) had a good accuracy (AUC = 0.80, p = 0.001) for prediction of severe EPS. CONCLUSIONS The incidence of EPS increases with PD duration. Severe EPS has high mortality rate and is associated with bowel tethering, presentation of bloody ascites, diagnosis after PD withdrawal, and higher serum levels of i-PTH before EPS diagnosis. Having 2 or more of the 5 risk factors can provide a good accuracy for prediction of severe EPS.
Collapse
Affiliation(s)
- Chin-Chung Tseng
- Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
- Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- * E-mail: (CCT); (CCH)
| | - Jin-Bor Chen
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung, Taiwan
| | - I-Kuan Wang
- Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan
| | - Shang-Chih Liao
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung, Taiwan
| | - Ben-Chung Cheng
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung, Taiwan
| | - An-bang Wu
- Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - Yu-Tzu Chang
- Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - Shih-Yuan Hung
- Division of Nephrology, Department of Internal Medicine, E-DA Hospital, and School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan
| | - Chiu-Ching Huang
- Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan
- * E-mail: (CCT); (CCH)
| |
Collapse
|
3
|
Latus J, Goffin E, Schroeder JA, Fritz P, Ott G, Ulmer C, Steurer W, Kimmel M, Biegger D, Segerer S, Alscher MD, Braun N. Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis. Perit Dial Int 2015; 34:561-5. [PMID: 25075001 DOI: 10.3747/pdi.2013.00137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Joerg Latus
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Eric Goffin
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Josef A Schroeder
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Peter Fritz
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - German Ott
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Christoph Ulmer
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Wolfgang Steurer
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Martin Kimmel
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Dagmar Biegger
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Stephan Segerer
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - M Dominik Alscher
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Niko Braun
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; Department of Nephrology, Université Catholique de Louvain, Cliniques Universitaires St Luc, Brussels, Belgium; Department of Pathology, Central EM Unit, University Medical Center, Regensburg, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; Department of General, Visceral and Trauma Surgery, Robert-Bosch Hospital, Stuttgart, Germany; Division of Nephrology, University Hospital, Zurich, Switzerland
| |
Collapse
|
4
|
Morelle J, Sow A, Hautem N, Bouzin C, Crott R, Devuyst O, Goffin E. Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis. J Am Soc Nephrol 2015; 26:2521-33. [PMID: 25636412 DOI: 10.1681/asn.2014090939] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2014] [Accepted: 12/24/2014] [Indexed: 12/27/2022] Open
Abstract
Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of peritoneal dialysis (PD) characterized by extensive fibrosis of the peritoneum. Changes in peritoneal water transport may precede EPS, but the mechanisms and potential predictive value of that transport defect are unknown. Among 234 patients with ESRD who initiated PD at our institution over a 20-year period, 7 subsequently developed EPS. We evaluated changes in peritoneal transport over time on PD in these 7 patients and in 28 matched controls using 3.86% glucose peritoneal equilibration tests. Compared with long-term PD controls, patients with EPS showed early loss of ultrafiltration capacity and sodium sieving before the onset of overt EPS. Multivariate analysis revealed that loss of sodium sieving was the most powerful predictor of EPS. Compared with long-term PD control and uremic peritoneum, EPS peritoneum showed thicker submesothelial fibrosis, with increased collagen density and a greater amount of thick collagen fibers. Reduced osmotic conductance strongly correlated with the degree of peritoneal fibrosis, but not with vasculopathy. Peritoneal fibrosis was paralleled by an excessive upregulation of vascular endothelial growth factor and endothelial nitric oxide synthase, but the expression of endothelial aquaporin-1 water channels was unaltered. Our findings suggest that an early and disproportionate reduction in osmotic conductance during the course of PD is an independent predictor of EPS. This functional change is linked to specific alterations of the collagen matrix in the peritoneal membrane of patients with EPS, thereby validating the serial three-pore membrane/fiber matrix and distributed models of peritoneal transport.
Collapse
Affiliation(s)
- Johann Morelle
- Division and Laboratory of Nephrology, Cliniques Universitaires Saint-Luc, Institute of Experimental and Clinical Research, Université Catholique de Louvain Medical School
| | - Amadou Sow
- Division and Laboratory of Nephrology, Cliniques Universitaires Saint-Luc, Institute of Experimental and Clinical Research, Université Catholique de Louvain Medical School
| | - Nicolas Hautem
- Division and Laboratory of Nephrology, Cliniques Universitaires Saint-Luc, Institute of Experimental and Clinical Research, Université Catholique de Louvain Medical School
| | - Caroline Bouzin
- Imaging Platform, Institute of Experimental and Clinical Research, and
| | - Ralph Crott
- School of Public Health, Université Catholique de Louvain Medical School, Brussels, Belgium; and
| | - Olivier Devuyst
- Division and Laboratory of Nephrology, Cliniques Universitaires Saint-Luc, Institute of Experimental and Clinical Research, Université Catholique de Louvain Medical School Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Eric Goffin
- Division and Laboratory of Nephrology, Cliniques Universitaires Saint-Luc, Institute of Experimental and Clinical Research, Université Catholique de Louvain Medical School
| |
Collapse
|
5
|
Hurst H, Summers A, Beaver K, Caress AL. Living with encapsulating peritoneal sclerosis (EPS): the patient's perspective. Perit Dial Int 2014; 34:758-65. [PMID: 24497592 PMCID: PMC4269501 DOI: 10.3747/pdi.2013.00053] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Accepted: 08/18/2013] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Although relatively rare, encapsulating peritoneal sclerosis (EPS) is nonetheless a major concern within the renal community. Risk of developing EPS is associated with long-term peritoneal dialysis (PD). High mortality was previously reported, although surgery has since improved outcomes. Research into EPS focuses on imaging and early detection methods, genetics, biomarkers and preventive strategies. No previous studies have examined patients' experiences of EPS. AIMS The aim of the present study was to explore the experience of patients who have undergone surgery for EPS in one center in the North of England. METHODS A qualitative phenomenological approach, involving in-depth interviews, was adopted. Nine participants were recruited out of a total of 18 eligible. Most participants were interviewed twice over a 12-month period (October 2009 to October 2010). ANALYSIS Interpretive data analysis was conducted, following the philosophical tradition of hermeneutics, to draw out themes from the data. Data collection and analysis took place concurrently and participants were sent a summary of their first interview to allow a period of reflection prior to the subsequent interview. RESULTS EPS presented the most serious challenge participants had faced since developing chronic kidney disease (CKD). Three major themes were identified, each with subcategories. The key issues for patients were related to identification of early symptoms and lack of understanding. The patients' sense of 'not being heard' by health care professionals led to a loss of trust and enhanced their feelings of uncertainty. The enormity of the surgery, the suffering, and what they had to endure had an enormous impact, but an overriding aspect of this experience was also the loss they felt for their independence and for the PD therapy over which they had control. CONCLUSIONS The findings of this study highlight a number of important issues relevant to clinical practice, including lack of information and understanding of EPS, particularly its early symptoms At the time patients transfer from peritoneal to hemodialysis, the provision of adequate information about the risks and potential early signs of EPS may not only improve their experiences, but may also assist in early detection.
Collapse
Affiliation(s)
- Helen Hurst
- Manchester University, Manchester, UK; Department of Renal Medicine Manchester Royal Infirmary (CMFT), Manchester, UK; University of Central Lancashire, Preston, UK; and University Hospital of South Manchester NHSFT, Manchester, UK
| | - Angela Summers
- Manchester University, Manchester, UK; Department of Renal Medicine Manchester Royal Infirmary (CMFT), Manchester, UK; University of Central Lancashire, Preston, UK; and University Hospital of South Manchester NHSFT, Manchester, UK
| | - Kinta Beaver
- Manchester University, Manchester, UK; Department of Renal Medicine Manchester Royal Infirmary (CMFT), Manchester, UK; University of Central Lancashire, Preston, UK; and University Hospital of South Manchester NHSFT, Manchester, UK
| | - Ann-Louise Caress
- Manchester University, Manchester, UK; Department of Renal Medicine Manchester Royal Infirmary (CMFT), Manchester, UK; University of Central Lancashire, Preston, UK; and University Hospital of South Manchester NHSFT, Manchester, UK
| |
Collapse
|
6
|
Latus J, Habib SM, Kitterer D, Korte MR, Ulmer C, Fritz P, Davies S, Lambie M, Alscher MD, Betjes MGH, Segerer S, Braun N. Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study. PLoS One 2014; 9:e106511. [PMID: 25171219 PMCID: PMC4149574 DOI: 10.1371/journal.pone.0106511] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Accepted: 07/30/2014] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Encapsulating peritoneal sclerosis (EPS) commonly presents after peritoneal dialysis has been stopped, either post-transplantation (PT-EPS) or after switching to hemodialysis (classical EPS, cEPS). The aim of the present study was to investigate whether PT-EPS and cEPS differ in morphology and clinical course. METHODS In this European multicenter study we included fifty-six EPS patients, retrospectively paired-matched for peritoneal dialysis (PD) duration. Twenty-eight patients developed EPS after renal transplantation, whereas the other twenty-eight patients were classical EPS patients. Demographic data, PD details, and course of disease were documented. Peritoneal biopsies of all patients were investigated using histological criteria. RESULTS Eighteen patients from the Netherlands and thirty-eight patients from Germany were included. Time on PD was 78(64-95) in the PT-EPS and 72(50-89) months in the cEPS group (p>0.05). There were no significant differences between the morphological findings of cEPS and PT-EPS. Podoplanin positive cells were a prominent feature in both groups, but with a similar distribution of the podoplanin patterns. Time between cessation of PD to the clinical diagnosis of EPS was significantly shorter in the PT-EPS group as compared to cEPS (4(2-9) months versus 23(7-24) months, p<0.001). Peritonitis rate was significantly higher in cEPS. CONCLUSIONS In peritoneal biopsies PT-EPS and cEPS are not distinguishable by histomorphology and immunohistochemistry, which argues against different entities. The critical phase for PT-EPS is during the first year after transplantation and therefore earlier after PD cessation then in cEPS.
Collapse
Affiliation(s)
- Joerg Latus
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany
| | - Sayed M. Habib
- Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Daniel Kitterer
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany
| | - Mario R. Korte
- Department of Internal Medicine, Division of Nephrology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
| | - Christoph Ulmer
- Department of General, Visceral and Trauma Surgery, Robert-Bosch-Hospital, Stuttgart, Germany
| | - Peter Fritz
- Department of Diagnostic Medicine, Division of Pathology, Robert-Bosch Hospital, Stuttgart, Germany
| | - Simon Davies
- Institute for Science and Technology in Medicine, Keele University, Keele, United Kingdom
| | - Mark Lambie
- Department of Nephrology, University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom
| | - M. Dominik Alscher
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany
| | - Michiel G. H. Betjes
- Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Stephan Segerer
- Division of Nephrology, University Hospital, Zurich, Switzerland
| | - Niko Braun
- Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany
- * E-mail:
| | | |
Collapse
|
7
|
De Sousa-Amorim E, Del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F, Bellon T, Selgas R. Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study. Perit Dial Int 2014; 34:582-93. [PMID: 24584614 DOI: 10.3747/pdi.2012.00286] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD). Identification of patients at high risk for EPS ("EPS-prone") and delivery of appropriate interventions might prevent its development. Our aim was to evaluate the clinical characteristics and outcomes of all EPS and EPS-prone patients diagnosed at our PD unit. METHODS For a 30-year period representing our entire PD experience, we retrospectively identified all patients with EPS (diagnosed according to International Society for Peritoneal Dialysis criteria) and all patients defined as EPS-prone because they met at least 2 established criteria (severe peritonitis, PD vintage greater than 3 years, severe hemoperitoneum, overexposure to glucose, and acquired ultrafiltration failure). RESULTS Of 679 PD patients, we identified 20 with EPS, for an overall prevalence of 2.9%. Mean age at diagnosis was 50.2 ± 16.4 years, with a median PD time of 77.96 months (range: 44.36 - 102.7 months) and a median follow-up of 30.91 months (range: 4.6 - 68.75 months). Of patients with EPS, 10 (50%) received tamoxifen, 10 (50%) received parenteral nutrition, and 2 (10%) underwent adhesiolysis, with 25% mortality related to EPS. Another 14 patients were identified as EPS-prone. Median follow-up was 54.05 months (range: 11.9 - 87.04 months). All received tamoxifen, and 5 (36%) received corticosteroids; none progressed to full EPS. We observed no differences in baseline data between the groups, but the group with EPS had been on PD longer (84 ± 53 months vs 39 ± 20 months, p = 0.002) and had a higher cumulative number of days of peritoneal inflammation from peritonitis (17.2 ± 11.1 days vs 9.8 ± 7.9 days, p = 0.015). Overall mortality was similar in the groups. The incidence of EPS declined during our three decades of experience (5.6%, 3.9%, and 0.3%). CONCLUSIONS Being a serious, life-threatening complication of PD, EPS requires high suspicion to allow for prompt diagnosis and treatment. Early detection of EPS-prone states and delivery of appropriate intervention might prevent EPS development. Tamoxifen seems to be a key strategy in prevention, but caution should be used in interpreting our results. Additional randomized controlled studies are needed.
Collapse
Affiliation(s)
- Erika De Sousa-Amorim
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Gloria Del Peso
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - M Auxiliadora Bajo
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Laura Alvarez
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Marta Ossorio
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Fernando Gil
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Teresa Bellon
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Rafael Selgas
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Madrid; Servicio de Nefrología, Hospital San Pedro, Logroño; and Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| |
Collapse
|
8
|
A case of encapsulating peritoneal sclerosis presented shortly after renal transplantation. CEN Case Rep 2013; 3:40-43. [PMID: 28509241 DOI: 10.1007/s13730-013-0079-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2012] [Accepted: 04/25/2013] [Indexed: 01/24/2023] Open
Abstract
Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis (PD), characterized by extensive intraperitoneal fibrosis and encasement of bowel loops. It typically associates with long-term PD and progressive loss of ultrafiltration. The management of EPS has evolved substantially from the original report of this entity and now includes immunosuppressive agents, antifibrotic agents, nutritional support, and surgical intervention. Although the exact cause of this condition remains obscure and despite the possible positive effect of immunosuppression on EPS, it has been described in the post-transplant setting upon the discontinuation of PD. We report such a case of a former PD patient who presented with EPS a month after renal transplantation. This article will highlight the current views regarding the management of post-transplant EPS and introduce the problem of long-term PD patients on the deceased-donor transplant waiting list.
Collapse
|
9
|
Vidal E, Edefonti A, Puteo F, Chimenz R, Gianoglio B, Lavoratti G, Leozappa G, Maringhini S, Mencarelli F, Pecoraro C, Ratsch IM, Cannavò R, De Palo T, Testa S, Murer L, Verrina E. Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients: the experience of the Italian Registry of Pediatric Chronic Dialysis. Nephrol Dial Transplant 2013; 28:1603-9. [DOI: 10.1093/ndt/gft061] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Enrico Vidal
- Pediatric Nephrology, Dialysis and Transplantation Unit, Department of Pediatrics, University of Padova, Padova, Italy
| | - Alberto Edefonti
- Pediatric Nephrology and Dialysis Unit, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Flora Puteo
- Nephrology Division, Giovanni XXIII Children's Hospital, Bari, Italy
| | - Roberto Chimenz
- Department of Pediatrics, Nephrology Unit, University School of Medicine, Messina, Italy
| | - Bruno Gianoglio
- Nephrology, Dialysis and Transplantation Unit, Regina Margherita Children's Hospital, Torino, Italy
| | | | - Giovanna Leozappa
- Nephrology and Urology Department, Bambino Gesù Children's Hospital, Roma, Italy
| | - Silvio Maringhini
- Pediatric Nephrology Unit, Children's Hospital ‘G. Di Cristina’, A.R.N.A.S. ‘Civico’, Palermo, Italy
| | - Francesca Mencarelli
- Nephrology and Dialysis Unit, Department of Pediatrics, Azienda Ospedaliero Universitaria Sant'Orsola-Malpighi, Bologna, Italy
| | - Carmine Pecoraro
- Nephrology and Dialysis Unit, Santobono Children's Hospital, Napoli, Italy
| | | | - Rossella Cannavò
- Dialysis Unit, Nephrology and Dialysis Division, IRCCS Giannina Gaslini, Genova, Italy
| | - Tommaso De Palo
- Nephrology Division, Giovanni XXIII Children's Hospital, Bari, Italy
| | - Sara Testa
- Pediatric Nephrology and Dialysis Unit, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Luisa Murer
- Pediatric Nephrology, Dialysis and Transplantation Unit, Department of Pediatrics, University of Padova, Padova, Italy
| | - Enrico Verrina
- Dialysis Unit, Nephrology and Dialysis Division, IRCCS Giannina Gaslini, Genova, Italy
| | | |
Collapse
|
10
|
Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T, Ott G, Kimmel M, Steurer W, Alscher MD, Segerer S, Braun N. Phenotypes of encapsulating peritoneal sclerosis--macroscopic appearance, histologic findings, and outcome. Perit Dial Int 2013; 33:495-502. [PMID: 23378473 DOI: 10.3747/pdi.2012.00019] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD), with clinical signs of abdominal pain, bowel obstruction, and weight loss in late stages. METHODS We retrospectively analyzed all patients who were diagnosed with EPS between March 1998 and October 2011 in our department of nephrology. We focused on the 24 EPS patients who underwent surgery because of symptomatic late-stage EPS. We identified 3 different macroscopic phenotypes of EPS that we categorized as types I - III. We correlated histologic findings with those macroscopic phenotypes of EPS. The postoperative and long-term outcomes were evaluated by macroscopic phenotype. RESULTS Duration of PD was longer in type III than in types I and II EPS (p = 0.05). We observed no other statistically significant differences between the groups in baseline characteristics, except for operation time, which was longer in the type I than in the type III group (p = 0.02). Furthermore, we observed no statistically significant difference between the groups with respect to the onset of complaints before surgery (7.8 ± 5.9 months vs 7.0 ± 7.0 months vs 6.5 ± 5.3 months). Concerning patient outcomes, there was no evidence that any of the macroscopic EPS types was associated with more major or minor complications after surgery. For all study patients, follow-up was at least 3 years, with 19 patients still being alive, and 16 having no or very mild complaints. The typical histologic findings of EPS were present in all macroscopic types; only fibrin deposits were more prominent in type II than in type III. CONCLUSIONS We describe 3 subtypes of EPS based on macroscopic findings. Postoperative treatment should probably not be influenced by the macroscopic EPS phenotype. Whether the different phenotypes represent different pathophysiologic processes remains unclear and has to be further evaluated.
Collapse
Affiliation(s)
- Joerg Latus
- Department of Internal Medicine,1 Division of Nephrology, Robert-Bosch-Hospital, and Department of General, Visceral and Trauma Surgery,2 Robert-Bosch-Hospital, Stuttgart, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Shroff R, Stefanidis CJ, Askiti V, Edefonti A, Testa S, Ekim M, Kavaz A, Ariceta G, Bakkaloglu S, Fischbach M, Klaus G, Zurowska A, Holtta T, Jankauskiene A, Vondrak K, Walle JV, Schmitt CP, Watson AR. Encapsulating peritoneal sclerosis in children on chronic PD: a survey from the European Paediatric Dialysis Working Group. Nephrol Dial Transplant 2013; 28:1908-14. [DOI: 10.1093/ndt/gfs603] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Rukshana Shroff
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | | | | | | | - Sara Testa
- Clinica Pediatrica De Marchi, Milan, Italy
| | | | - Asli Kavaz
- Ankara University Hospital, Ankara, Turkey
| | | | | | | | | | | | | | | | | | | | | | - Alan R. Watson
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | | |
Collapse
|
12
|
Braun N, Fritz P, Ulmer C, Latus J, Kimmel M, Biegger D, Ott G, Reimold F, Thon KP, Dippon J, Segerer S, Alscher MD. Histological criteria for encapsulating peritoneal sclerosis - a standardized approach. PLoS One 2012; 7:e48647. [PMID: 23144917 PMCID: PMC3492493 DOI: 10.1371/journal.pone.0048647] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Accepted: 09/27/2012] [Indexed: 12/11/2022] Open
Abstract
Background The two most relevant pathologies of long-term peritoneal dialysis (PD) are simple sclerosis and encapsulating peritoneal sclerosis (EPS). The histological differentiation of those two entities is difficult. The Aim of the study was to establish a method to standardize and facilitate the differentiation between simple sclerosis and EPS Methods We investigated 58 peritoneal biopsies - 31 EPS patients and 27 PD patients. Two blinded investigators analyzed 20 histological characteristics in EPS and PD patients. Results The following findings were significantly more common in EPS than in patients on PD without EPS: fibroblast like cells (FLC) (p<0.0001), mesothelial denudation (p<0.0001), decreased cellularity (p = 0.008), fibrin deposits (p<0.03), Fe deposits (p = 0.05), podoplanin vascular (p<0.0001), podoplanin avascular (p<0.0001). Using all predictor variables we trained the classification method Random Forest to categorize future cases. Podoplanin vascular and avascular were taken together (p<0.0001), FLC (p<0.0001), mesothelial denudation (p = 0.0005), calcification (p = 0.0026), acellular areas (p = 0.0094), and fibrin deposits (p = 0.0336) showed up as significantly important predictor variables. Estimated misclassification error rate when classifying new cases turned out to be 14%. Conclusion The introduced statistical method allows discriminating between simple sclerosis and EPS. The misclassification error will likely improve with every new case added to the database.
Collapse
Affiliation(s)
- Niko Braun
- Department of Internal Medicine, Division of Nephrology, Robert Bosch Hospital, Stuttgart, Germany
| | - Peter Fritz
- Margarete Fischer–Bosch Institute of Clinical Pharmacology, University of Tuebingen, Tuebingen, Germany
| | - Christoph Ulmer
- Department of Surgery, Robert Bosch Hospital, Stuttgart, Germany
| | - Joerg Latus
- Department of Internal Medicine, Division of Nephrology, Robert Bosch Hospital, Stuttgart, Germany
- * E-mail:
| | - Martin Kimmel
- Department of Internal Medicine, Division of Nephrology, Robert Bosch Hospital, Stuttgart, Germany
| | - Dagmar Biegger
- Margarete Fischer–Bosch Institute of Clinical Pharmacology, University of Tuebingen, Tuebingen, Germany
| | - German Ott
- Department of Diagnostic Medicine, Division of Pathology, Robert Bosch Hospital, Stuttgart, Germany
| | - Fabian Reimold
- Department of Internal Medicine, Division of Nephrology, Robert Bosch Hospital, Stuttgart, Germany
- Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
| | - Klaus-Peter Thon
- Department of Surgery, Robert Bosch Hospital, Stuttgart, Germany
| | - Juergen Dippon
- Department of Mathematics, University of Stuttgart, Stuttgart, Germany
| | - Stephan Segerer
- Division of Nephrology, University Hospital, Zurich, Switzerland
| | - M. Dominik Alscher
- Department of Internal Medicine, Division of Nephrology, Robert Bosch Hospital, Stuttgart, Germany
| |
Collapse
|
13
|
Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T, Ott G, Scharpf C, Kimmel M, Steurer W, Alscher MD, Braun N. Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis–experience of a referral centre in Germany. Nephrol Dial Transplant 2012; 28:1021-30. [DOI: 10.1093/ndt/gfs159] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Braun N, Alscher MD, Kimmel M, Amann K, Büttner M. Encapsulating peritoneal sclerosis – an overview. Nephrol Ther 2011; 7:162-71. [DOI: 10.1016/j.nephro.2010.12.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2010] [Accepted: 12/28/2010] [Indexed: 12/21/2022]
|